Background and Purpose: Super-selective thrombolytic therapy (STT) has only been applied in patients with brain embolism associated with known abnormalities such as atrial fibrillation in Japan. The purpose of this study is to report our experience with this therapy for acute phase atherothrombotic brain ischemia (TBI) to prevent from infarction. We compare the results of our study in patients with TBI with those of the same treatment in patients with embolic brain ischemia (EBI). Methods: STT consisted of intraarterial delivery of urokinase (UK) as the thrombolytic agent to the site of occlusion in 21 patients (10 patients with TBI and 11 with EBI). The maximum dose of UK used was 240,000IU. Immediate or rescue percutaneous transluminal angioplasty (PTA) was subsequently performed when recanalization failed or post-STT stenosis was>90%. The rates of successful recanalization, improvement of symptoms, required PTA, and occurrence of acute bleeding, and the total dose of UK, were compared between the two groups. Results: STT resulted in successful recanalization in all patients of both groups. The proportions of patients showing improvement of symptoms, required PTA, and those who developed acute bleeding, and the average dose of UK, were 90 and 73%, 10 and 9%, 10 and 18%, 114,000 and 131,000IU in TBI and EBI groups, respectively. There were no significance differences in the above parameters between the two groups. Conclusions: The results of our STT showed high rate of improvement for TBI as well as EBI. We believe this STT will be a rather safe and recommendable treatment for the acute phase of TBI, as the catheters are improving continuously. (JJAAM 2001; 12: 360-5) 
Introduction
In December, 1996, we started a clinical trial of superselective thrombolytic treatment for patients with cerebral ischemic attack in our department soon after fine catheters for brain arteries became available commercially. Our results so far suggest that super-selective thrombolytic therapy applied locally at the site of occlusion is a very promising treatment particularly when performed within a short period after the onset of cerebral infarction.
However, this therapy has only been applied in patients with brain embolism associated with known abnormalities such as atrial fibrillation. Local thrombolytic therapy
has not yet been applied during the acute phase in patients with TBI in Japan. In this report, we present the results of our preliminary study using STT in 10 cases with acute phase TBI as well as 11 cases of EBI. Data represent the number of patients (percentages). UK=urokinase; PTA=percutaneous transluminal angioplasty There were no differences in the above parameters between the two groups.
Subjects and Methods
performed rescue or immediate PTA with balloon catheter. The balloon was 2.0 to 3.0 diameter and inflated once or twice to 3 to 4atm for 10 to 30 seconds. Immediately after securing recanalization, nicardipine hydrochloride (1-2mg) diluted with physiological saline was injected intravenously to lower blood pressure, which is often elevated in such patients. Heparin was also injected intravenously at 5,000U before thrombolysis. This was followed by continuous infusion of 500U/hour for 24 hours and oral administration of ticlopidine hydrochloride (200mg/day) after thrombolysis.
Brain CT scan was performed soon after STT and repeated on the next day to ensure the absence of any bleeding or distal embolization.
Neurological status was evaluated on admission and one week after treatment when the brain edema due to ischemia had subsided. The Rankin's stroke scale rather than National Institute of Health stroke scale was used in our study for its convenience in evaluating unconscious patients5).
Materials
Urokinase used for thrombolysis was purchased from Mochida Pharmaceutical Company, Japan. The tools used were guiding catheter (Guider, Target, USA), microcatheter (Micro-soft Stream, Target), guidewire (Transend, Scimed, USA), and balloon catheter (Fas STEALTH, Target).
Statistical analysis
Differences between groups were examined for statistical significance using the Student's t-test and Fisher's Other features of the TBI and EBI groups are summarized in Tables 2 and 3 , respectively. Complications encountered in this series of patients were minimal; patient 4 of TBI group developed a distal embolism of the right MCA and acute subcortical hemorrhage during STT (about 4ml of blood). In patient 7, STT resulted in recanalization but stenosis was still at 90%, thus necessitating immediate PTA.
Discussion
Our results so far suggest that thrombolytic therapy applied locally at the site of occlusion is a very promising treatment particularly when performed within a short period after the onset of cerebral ischemia. However, this therapy has only been applied in patients with brain embolism associated with known abnormalities such as atrial fibrillation6). Thrombolytic therapy has not yet been applied during the acute phase in patients with atherothrombosis. Our results emphasize that STT using improved catheters at the site of the atherosclerotic focus is applicable in patients with cerebral ischemia caused by thrombosis. Application of this method was not associated with severe constriction at the site of thrombus formation, PTA was only required in 1 case. The degree of post-STT stenosis ranged from 25% to 75% of that seen in coronary arteries in myocardial infarction. Furthermore, the local thrombus was very soft, allowing easy penetration of the guidewire or microcatheter. Initially, we doubted that these maneuvers could be performed as we expected the site of obstruction to be almost completely constricted and also anticipated the presence of a large thrombus filling a long segment of the artery. Contrary to these expectations, the size of the thrombus was actually small and the distal brain embolism seemed rare, compared with brain embolism due to cardiac clot.
Ueda et al indicated in their report of a similar study, that the dose of UK used was 640,000IU on average in those patients who underwent intraarterial thrombolysis, and 630,000IU in the PTA group7). They also indicated that the doses of various thrombolytic agents did not correlate with the incidence of hemorrhagic transformation8). Jahan et al, however, indicate that the average dose of UK was higher in the hemorrhage group9). In our series, however, we did not use such a high dose of UK since we were apprehensive of the development of acute undetectable hemorrhage occurring during UK injection.
PTA is currently actively performed for atherosclerotic coronary arteries and peripheral arteries but the risks of dissection, restenotic obstruction, and rapid growth of a new thrombus on the ruptured plaque by dilatation must be always considered. In the present technique, one must be prudent when performing PTA of intracranial arteries because there is no technique at present to insert firm STENT into the winding narrow arteries.
In the case of ICA obstruction, the collateral circulation is very poor, and thus severe cerebral edema and/or hemorrhage tend to occur after recanalization9,10). Furthermore, distal embolism frequently occurs because the total volume of the thrombus is larger than that of the small distal intracranial arteries. Such complication is frequently seen in both TBI and EBI, applications of STT need further study in order to obtain good results9).
In TBI, on the other hand, the onset of attack is gradual in contrast to EBI, and this is often associated with a gradual decrease in local blood flow. These changes, however, enhance the development of collateral circulation. If a preconditioning state occurs in brain cells like in the myocardium, the cerebral tissues of patients with TBI would tolerate ischemia for longer period of time than patients with EBI. Acute brain ischemia was previously treated by systemic administration of large quantities of UK or strep-tokinase11). However, such treatment was only to produce frequent hemorrhagic infarction especially in brain embolism. After the use of fine microcatheters were introduced for the treatment of atherosclerotic coronary arteries and later refined for use in cerebral arteries, such catheters are now available for the embolization of aneurysms and thrombolysis of emboli in the cerebral arteries. The use of these catheters also tended to be associated with a reduction in the dose of UK used in these patients and high recanalization rate, excellent improvement of symptoms and lower hemorrhage rate, compared to the conventional intraarterial or intravenous thrombol-ysls12-14).
Clinical trials are currently being conducted to test the usefulness of systemic administration of high dose of recombinant tissue plasminogen activator (rtPA) in acute brain ischemia15-17). While such treatment is simple and easy to administer, the recanalization rate is lower and hemorrhagic rate is higher than the technique described in our report [18] [19] [20] . In particular, severe bleeding may occur in ICA occlusion unless rtPA is administered within 1 or 2 hours after onset. It is advisable that systemic administration of tPA in large quantities by nonspecialists should be discouraged in order to avoid failure of hemorrhagic infarction experienced in the past.
